Medication info

Kwangdong Empaglo Tablet 25 mg (Empagliflozin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›25mg / 1 tablet
Manufacturer / importer
Kwangdong Pharmaceutical Co., Ltd.
Appearance
Pale yellow oval film-coated tablet
Packaging
30 tablets/PTP (10 tablets/PTP×3), 10 tablets/PTP (10 tablets/PTP×1)
Approval status
Active

MFDS item code 202105607 · Approved 2021.07.29

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine for monotherapy and as add-on combination therapy with other glucose-lowering agents, including insulin, is 10 mg once daily. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This medicine may be taken regardless of food. Swallow the tablet whole. If a dose is missed, take it as soon as remembered. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Do not initiate treatment with this medicine in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], adjust or maintain the dose of this medicine at 10 mg once daily. Discontinue this medicine if the estimated glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those undergoing dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as they have not been studied. •Older adults No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years and older. Initiation of this medicine is not recommended in patients aged 85 years and older because clinical experience is limited (see Precautions for Use, section 4. General Precautions)

Ingredients

Manufacturer
Kwangdong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • impaired blood sugar control
  • cardiovascular diseases
  • cardiovascular events
View approved original text

This medication is used as an adjunct to diet and exercise in adult patients with type 2 diabetes. It helps improve blood sugar control alone or in combination with other medications. It plays an important role in managing the risk of cardiovascular events in type 2 diabetes patients who do not achieve adequate glycemic control, particularly those with cardiovascular disease. This medication contributes to maintaining health by effectively managing blood sugar levels.

How to take

Adult dose

The recommended dose of this medicine for monotherapy and as add-on combination therapy with other glucose-lowering agents, including insulin, is 10 mg once daily. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This medicine may be taken regardless of food. Swallow the tablet whole. If a dose is missed, take it as soon as remembered. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Do not initiate treatment with this medicine in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], adjust or maintain the dose of this medicine at 10 mg once daily. Discontinue this medicine if the estimated glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those undergoing dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as they have not been studied. •Older adults No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years and older. Initiation of this medicine is not recommended in patients aged 85 years and older because clinical experience is limited (see Precautions for Use, section 4. General Precautions)

Precautions

This medication should not be used in certain patients. First, it should not be administered to patients with known allergies to its components. Second, it is not for use in patients with type 1 diabetes or diabetic ketoacidosis. Third, it should not be given to patients with severely impaired renal function, end-stage renal disease, or those on dialysis. Fourth, since this medication contains lactose, patients with lactose intolerance or galactose metabolism disorders should avoid it. When using this medication, caution is especially advised in patients with reduced renal function. If renal function falls below a certain level, the dose of this medication should be reduced or use should be discontinued. It is not expected to be effective in patients with end-stage renal disease or those on dialysis. It should be used cautiously in patients with mild heart failure, and is not recommended for patients with severe heart failure. The risk of hypoglycemia may increase when used in combination with other hypoglycemic agents like insulin or sulfonylureas, so dosage adjustments of these medications may be necessary. Side effects such as hypoglycemia, genital infections, urinary tract infections, increased urination, decreased fluid volume, liver function abnormalities, etc., may occur during treatment; therefore, attention to symptoms is crucial. Particularly, serious metabolic disturbances such as ketoacidosis may occur, so if symptoms like vomiting, abdominal pain, or difficulty breathing arise, immediate consultation with a physician is necessary. Elderly patients or those at risk of fluid volume loss should be cautious of dehydration or hypotension, and may require temporary discontinuation of this medication. Additionally, this medication may increase the risk of genital fungal infections, so treatment is needed if symptoms of infection appear. Glucose may be detected on urinalysis during the course of this medication, so please be aware. Pregnant or breastfeeding women are advised to avoid the use of this medication, and it should be discontinued upon confirmation of pregnancy. Safety and efficacy in pediatric patients have not been established, therefore it should not be used in patients under 18 years of age. In the case of overdose, appropriate treatment should be administered based on the patient's condition; the removal effect through hemodialysis is not known. This medication should be kept out of the reach of children and is not recommended to be transferred to another container. Caution should be taken when driving or operating machinery considering the risk of hypoglycemia. Finally, while this medication aids in blood sugar control, appropriate dose adjustments and regular monitoring are required based on the patient’s condition.

Side effects

  • Hypoglycemia
  • ketoacidosis
  • vulvovaginitis
  • balanitis
  • other genital infections
  • urinary tract infection
  • perineal necrosis
  • pruritus
  • rash
  • urticaria
Show 12 more
  • angioedema
  • decreased fluid volume
  • increased urination
  • urination difficulties
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased blood creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • urosepsis
  • pyelonephritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture from entering. It should be kept at normal room temperature between 1 to 30 degrees Celsius, avoiding excessively hot or cold places.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablet

Package unit

30 tablets/PTP (10 tablets/PTP×3), 10 tablets/PTP (10 tablets/PTP×1)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.